SCHEMBL10078847

SCHEMBL10078847

CN1CC(Oc2ccc(F)cc2)C1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.47
HTR2B P41595 1/20 0.47
LIPG Q9Y5X9 2/20 0.42
HRH3 Q9Y5N1 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SLC6A4 P31645 1/20 0.41
FPR2 P25090 1/20 0.41
PROKR1 Q8TCW9 1/20 0.41
GRIN1 Q05586 3/20 0.40
GRIN2B Q13224 3/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
SCN9A Q15858 1/20 0.40
EPHX2 P34913 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10262288 0.87 HTR2C (0.60) HTR2CHTR2BLIPGHRH3MAPT
SCHEMBL10079036 0.87 HTR2C (0.60) HTR2CHTR2BLIPGHRH3MAPT
SCHEMBL10261788 0.87 HTR2C (0.60) HTR2CHTR2BLIPGHRH3MAPT
SCHEMBL9681971 0.82 ALDH1A1 (0.51) HRH3MAPTSMN1; SMN2SLC6A4ALDH1A1
SCHEMBL20217571 0.82 HTR2C (0.46) HTR2CHTR2BHRH3MAPTSMN1; SMN2
SCHEMBL30921290 0.82 TDP1 (0.43) HRH3MAPTSMN1; SMN2ALDH1A1
SCHEMBL10274500 0.81 HRH3 (0.63) HTR2CHTR2BHRH3MAPTSMN1; SMN2
SCHEMBL14873944 0.80 LIPG (0.42) HTR2CHTR2BLIPGGRIN1GRIN2B
SCHEMBL16291964 0.80 HRH3 (0.41) HRH3SMN1; SMN2SLC6A4ALDH1A1EPHX2
SCHEMBL20176333 0.80 SLC6A4 (0.38) HTR2CHTR2BSLC6A4GRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018102384-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2018-06-07 WO disclosed
WO-2018071454-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed
US-8148404-B2 Modulators of CB1 receptors 7TM PHARMA A/S (DK) 2012-04-03 US disclosed
US-20100144701-A1 Modulators of CB1 Receptors 7TM PHARMA A/S (DK) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144701-A1 Modulators of CB1 Receptors CNR1, CNR2, GPR6 HTR2C 582/4885HTR2B 487/4885LIPG 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.